Skip to main content

Search articles in Healthcare

Found 36 articles

  • Gilead and the Elton John AIDS Foundation Announce

    Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

    • 22 Jul 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) today announced a five-year extension of the RADIAN ® partnership to help meet the needs of the most vulnerable key populations in Eastern Europe and Central Asia (EECA) where the HIV epidemic is growing.

  • IQVIA’s SmartSolve® eQMS Wins 2024 MedTech Breakth

    IQVIA’s SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”

    • 26 Jun 2024
    • Editor

    IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards.

  • ABBOTT TEAMS UP WITH THE NATIONAL ASSOCIATION OF C

    ABBOTT TEAMS UP WITH THE NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS TO EXPAND ACCESS TO NUTRITIOUS FOOD AND IMPROVE HEALTH

    • 21 Jun 2024
    • Editor

    The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative.

  • Make World Dengue Day a Reality

    Make World Dengue Day a Reality

    • 17 Jun 2024
    • Editor

    Whilst WDD is widely backed and recognised on 15th June by the International Society for Neglected Tropical Diseases (ISNTD), Asian Dengue Voice and Action (ADVA) Group and dengue scientists around the world, it is not yet recognised by the United Nations.

  • AbbVie Launches First-of-its-Kind Contest to Empow

    AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

    • 7 Jun 2024
    • Editor

    AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine. With more than 113 million workdays lost in the U.S. each year to the disease and its symptoms, migraine can have a major impact in the workplace.

  • GeneType and Stayhealthy Announce Landmark Distrib

    GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

    • 6 Jun 2024
    • Editor

    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement.

  • Lilly, UNICEF expand support to help millions of y

    Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

    • 30 May 2024
    • Editor

    During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India.

  • Jazz Pharmaceuticals Announces Collaboration with

    Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

    • 23 May 2024
    • Editor

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States.

  • Bristol Myers Squibb, Taye Diggs and Schizophrenia

    Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign

    • 22 May 2024
    • Editor

    Bristol Myers Squibb (NYSE: BMY) today announced the launch of Live Your PosSCZible, a national campaign in partnership with the schizophrenia community focused on elevating lived experiences and empowering patients and care partners with educational, community and peer resources to help navigate care.

  • Labcorp Introduces First Trimester Screening Test

    Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy

    • 16 May 2024
    • Editor

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy.

  • GSK to become a founding partner of Fleming Initia

    GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)

    • 16 May 2024
    • Editor

    Global biopharmaceutical company, GSK, will become the first founding partner of the Fleming Initiative, an innovative and collaborative approach led by Imperial College Healthcare NHS Trust and Imperial College London to tackle antimicrobial resistance (AMR) around the world.

  • Baxter Announces Mission and Logo for Proposed Kid

    Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive

    • 16 May 2024
    • Editor

    Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.

  • Merck Expands Access to High-Quality Maternal Care

    Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers

    • 9 May 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative, has reached more than 30 million women through programs promoting safe, high-quality, respectful care, surpassing its goal of reaching 25 million women by 2025.

  • Fresenius divests Vamed’s rehabilitation business

    Fresenius divests Vamed’s rehabilitation business

    • 3 May 2024
    • Editor

    The global healthcare group Fresenius is continuing to drive its portfolio optimization. The company has reached an agreement with PAI for the sale of the majority of Vamed’s rehabilitation business.

  • Merck Announces Positive Data for V116, an Investi

    Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

    • 30 Apr 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain.

  • Wegovy® approved in the US for cardiovascular risk

    Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

    • 11 Mar 2024
    • Editor

    Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).

  • Lilly's Newest Phase of Get Better Campaign Challe

    Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

    • 8 Mar 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

  • Lilly Launches End-to-End Digital Healthcare Exper

    Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

    • 5 Jan 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.

  • Roche named among top three most sustainable healt

    Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

    • 15 Dec 2023
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). Roche ranked third, Chugai Pharmaceuticals, a member of the Roche Group, ranked second.

  • ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatm

    ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

    • 15 Dec 2023
    • Editor

    Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients.